61629-60-5 Usage
Main properties
1. Chemical compound: 3-[4-[2-[(5-chloro-2-methoxy-benzoyl)amino]ethyl]phenyl]propanoic acid
2. Category: Nonsteroidal anti-inflammatory drugs (NSAIDs)
3. Derivative: Propanoic acid
Specific content
1. Purpose: Used for its anti-inflammatory, analgesic, and antipyretic properties
2. Mechanism of action: Inhibits the production of prostaglandins, which are mediators of inflammation and pain
3. Uses: Effective in the treatment of conditions such as arthritis, menstrual pain, and fever
4. Chemical structure: Contains a 5-chloro-2-methoxy-benzoyl group
5. Mode of action: Targets certain enzymes involved in the inflammatory process
Check Digit Verification of cas no
The CAS Registry Mumber 61629-60-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,1,6,2 and 9 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 61629-60:
(7*6)+(6*1)+(5*6)+(4*2)+(3*9)+(2*6)+(1*0)=125
125 % 10 = 5
So 61629-60-5 is a valid CAS Registry Number.
InChI:InChI=1/C19H20ClNO4/c1-25-17-8-7-15(20)12-16(17)19(24)21-11-10-14-4-2-13(3-5-14)6-9-18(22)23/h2-5,7-8,12H,6,9-11H2,1H3,(H,21,24)(H,22,23)
61629-60-5Relevant articles and documents
Preparation of phenylethylbenzamide derivatives as modulators of DNMT3 activity
Kabro, Anzhelika,Lachance, Hugo,Marcoux-Archambault, Iris,Perrier, Valerie,Dore, Vicky,Gros, Christina,Masson, Veronique,Gregoire, Jean-Marc,Ausseil, Frederic,Cheishvili, David,Laulan, Nathalie Bibens,St-Pierre, Yves,Szyf, Moshe,Arimondo, Paola B.,Gagnon, Alexandre
, p. 1562 - 1570 (2013/12/04)
DNA-methyltransferases (DNMTs) are a class of epigenetic enzymes that catalyze the transfer of a methyl moiety from the methyl donor S-adenosyl-l-methionine onto the C5 position of cytosine in DNA. This process is dysregulated in cancers and leads to the hypermethylation and silencing of tumor suppressor genes. The development of potent and selective inhibitors of DNMTs is of utmost importance for the discovery of new therapies for the treatment of cancer. We report herein the synthesis and DNMT inhibitory activity of 29 analogues derived from NSC 319745. The effect of selected compounds on the methylation level in the MDA-MB-231 human breast cancer cell line was evaluated using a luminometric methylation assay. Molecular docking studies have been conducted to propose a binding mode for this series.